EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species

Krisztina M Papp-Wallace, Sarah M McLeod, Alita A Miller

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Krisztina M Papp-Wallace und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, Veterans Affairs Northeast Ohio Healthcare System, USA. Hauptthemen laut MEDLINE: Acinetobacter Infections, Acinetobacter baumannii. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination in late-stage development for the treatment of Acinetobacter infections, including those caused by multidrug-resistant strains. Durlobactam is a member of the diazabicyclooctane class of β-lactamase inhibitors with broad-spectrum serine β-lactamase activity. Sulbactam is a first-generation, narrow-spectrum β-lactamase inhibitor that also has intrinsic antibacterial activity against Acinetobacter spp. due to its ability to inhibit penicillin-binding proteins 1 and 3. The clinical utility of sulbactam for the treatment of contemporary Acinetobacter infections has been eroded over the last decades due to its susceptibility to cleavage by numerous β-lactamases present in this species. However, when combined with durlobactam, the activity of sulbactam is restored against this problematic pathogen. The following summary describes what is known about the molecular drivers of activity and resistance as well as results from surveillance and in vivo efficacy studies for this novel combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter InfectionsAcinetobacter baumanniiHumansSulbactambeta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesMicrobial Sensitivity TestsAzabicyclo Compounds

Stichwörter der Autor:innen

Acinetobacterdiazabicyclooctanedurlobactamsulbactamβ-lactamase inhibitor

Substanzen

Sulbactambeta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesdurlobactamAzabicyclo Compounds

Autor:innen und Institutionen

  • Research Service, Veterans Affairs Northeast Ohio Healthcare System, USA.
  • Departments of Biochemistry and Medicine, Case Western Reserve University, Cleveland, OH, USA.
  • Entasis Therapeutics, Waltham, MA, USA.

Zitieren

APA

Papp-Wallace, K. M., McLeod, S. M., & Miller, A. A. (2023). Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad095

Vancouver

Papp-Wallace KM, McLeod SM, Miller AA. Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad095

BibTeX
@article{PappWallace2023,
  author = {Papp-Wallace, Krisztina M and McLeod, Sarah M and Miller, Alita A},
  title = {Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad095}
}
Kostenlos starten →